EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib

International Journal of Cancer

Volumn 131, Issue 12, 2012, Pages 2961-2969

  Ezzoukhry, Zakaria ^a,b   Louandre, Christophe ^a,b   Trécherel, Eric ^a,b   Godin, Corinne ^a,b   Chauffert, Bruno ^c   Dupont, Sébastien ^a   Diouf, Momar ^b   Barbare, Jean Claude ^b   Mazière, Jean Claude ^a,b   Galmiche, Antoine ^a,b  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

EGFR; hepatocellular carcinoma; RAF kinases; resistance; sorafenib

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; SORAFENIB;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER RESISTANCE; CELL PROLIFERATION; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; HEPATOMA CELL; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; PYRIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE;

EID: 84867843356     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27604     Document Type: Article

References (34)

1. El-Serag HB,. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.
2. Villanueva A, Minguez B, Forner A, et al. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010; 61: 317-28.
3. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
4. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-300.
5. Abou-Alfa GK,. Selection of patients with hepatocellular carcinoma for sorafenib. J Natl Compr Canc Networks 2009; 7: 397-403.
6. Wellbrock C, Karasarides M, Marais R,. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004; 5: 875-85.
7. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006; 130: 1117-28.
8. Lee SA, Ladu S, Evert M, et al. Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. Hepatology 2010; 52: 506-17.
9. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-21.
10. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-5.
11. Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464: 427-30.
12. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973-7.
13. Huynh H, Ngo VC, Koong HN, et al. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol 2010; 52: 79-87.
14. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-10.
15. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-8.
16. Seitz SJ, Schleithoff ES, Koch A, et al. Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int J Cancer 2010; 126: 2049-66.
17. Park JG, Lee JH, Kang MS, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer 1995; 62: 276-82.
18. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
19. Galmiche A, Ezzoukhry Z, François C, et al. BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. Mol Cancer Res 2010; 8: 1116-25.
20. Bublil EM, Yarden Y,. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19: 124-34.
21. Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-11.
22. Castillo J, Erroba E, Perugorría MJ, et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 2006; 66: 6129-38.
23. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353: 2012-24.
24. Arnault JP, Mateus C, Escudier B, et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res 2012; 18: 263-72.
25. Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001; 84: 1377-83.
26. Buckley AF, Burgart LJ, Sahai V, et al. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 2008; 129: 245-51.
27. Su MC, Lien HC, Jeng YM,. Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. Cancer Lett 2005; 224: 117-21.
28. Höpfner M, Sutter AP, Huether A, et al. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 2004; 41: 1008-16.
29. Huether A, Höpfner M, Sutter AP, et al. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 2005; 43: 661-9.
30. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657-63.
31. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110: 1059-67.
32. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 581-9.
33. Gridelli C, Morgillo F, Favaretto A, et al. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Ann Oncol 2011; 22: 1528-34.
34. Spigel DR, Burris HA, III, Greco FA, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 2582-9.